Home › Companies › HALOZYME THERAPEUTICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and HALOZYME THERAPEUTICS INC.’s Form 8-K, filed April 26, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of April 25, 2024: 5 items on HALOZYME THERAPEUTICS INC.’s Form 8-K, filed April 26, 2024: 3 approved · 2 passed (calculated).
Notable dissent: 1 director (14.3% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore HALOZYME THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are HALOZYME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 26, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Barbara Duncan | 90,120,424 | 15,016,536 | 161,704 | -- | 10,383,116 | 86% | Passed (calculated) | — |
| Elect Director: Mahesh Krishnan, M.D. | 103,968,663 | 1,164,017 | 165,984 | -- | 10,383,116 | 99% | Passed (calculated) | — |
| 2. Advisory vote on the compensation of the Company's named executive officers | 102,860,435 | 2,190,603 | 247,626 | -- | 10,383,116 | 98% | Approved | — |
| 3. Proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers | 91,512,252 | 13,612,616 | 173,796 | -- | 10,383,116 | 87% | Approved | — |
| 4. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 114,912,469 | 647,868 | 121,443 | -- | -- | 99.4% | Approved | — |
This meeting is also recorded here as April 26, 2024; both records come from the same filing, so the date should be checked against it.
Source: HALOZYME THERAPEUTICS INC., Form 8-K, filed with the SEC on April 26, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
434 asset managers disclosed a vote on at least one HALOZYME THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Barbara Duncan
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Barbara Duncan”): 90,120,424 for, 15,016,536 against, per its Form 8-K filed April 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 123 asset managers below reported 52,576,135 for, 7,776,543 against, 62,687 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,892,835 | 0 | 0 | 0 | For |
| BlackRock | 10,711,138 | 0 | 0 | 0 | For |
| Fidelity | 3,209,068 | 44,852 | 0 | 0 | For |
| State Street | 58,372 | 2,768,522 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 2,076,163 | 0 | 0 | Against |
| Artisan | 2,028,425 | 0 | 0 | 0 | For |
| Charles Schwab | 1,720,061 | 0 | 0 | 0 | For |
| Thrivent | 1,695,443 | 0 | 0 | 0 | For |
| JPMorgan | 1,623,745 | 0 | 0 | 0 | For |
| TIAA | 1,460,481 | 0 | 0 | 0 | For |
| First Trust | 1,201,533 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,059,054 | 0 | 0 | 0 | For |
| Invesco | 0 | 1,004,224 | 0 | 0 | Against |
| T. Rowe Price | 970,596 | 0 | 0 | 0 | For |
| Dimensional | 815,846 | 0 | 0 | 0 | For |
| Jackson National | 455,295 | 340,856 | 0 | 0 | Mixed |
| Equitable | 720,924 | 0 | 0 | 0 | For |
| American Century | 682,192 | 0 | 0 | 0 | For |
| Brighthouse | 144,234 | 413,107 | 0 | 0 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 500,392 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 482,634 | 0 | 0 | 0 | For |
| Federated Hermes | 468,804 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 461,935 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 380,360 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 372,820 | 0 | 0 | 0 | For |
Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Mahesh Krishnan
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mahesh Krishnan, M.D.”): 103,968,663 for, 1,164,017 against, per its Form 8-K filed April 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 123 asset managers below reported 60,091,787 for, 260,891 against, 62,687 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,892,835 | 0 | 0 | 0 | For |
| BlackRock | 10,711,138 | 0 | 0 | 0 | For |
| Fidelity | 3,209,068 | 44,852 | 0 | 0 | For |
| State Street | 2,826,894 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 2,076,163 | 0 | 0 | 0 | For |
| Artisan | 2,028,425 | 0 | 0 | 0 | For |
| Charles Schwab | 1,720,061 | 0 | 0 | 0 | For |
| Thrivent | 1,695,443 | 0 | 0 | 0 | For |
| JPMorgan | 1,623,745 | 0 | 0 | 0 | For |
| TIAA | 1,460,481 | 0 | 0 | 0 | For |
| First Trust | 1,201,533 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,059,054 | 0 | 0 | 0 | For |
| Invesco | 1,004,224 | 0 | 0 | 0 | For |
| T. Rowe Price | 970,596 | 0 | 0 | 0 | For |
| Dimensional | 815,846 | 0 | 0 | 0 | For |
| Jackson National | 796,151 | 0 | 0 | 0 | For |
| Equitable | 720,924 | 0 | 0 | 0 | For |
| American Century | 682,192 | 0 | 0 | 0 | For |
| Brighthouse | 557,341 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 500,392 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 482,634 | 0 | 0 | 0 | For |
| Federated Hermes | 468,804 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 461,935 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 380,360 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 372,820 | 0 | 0 | 0 | For |
Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
87% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers.
HALOZYME THERAPEUTICS INC.’s own tally for this item (“3. A proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers”): 91,512,252 for, 13,612,616 against — passed, per its Form 8-K filed April 26, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 123 asset managers below reported 55,677,455 for, 4,675,989 against, 61,921 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,782,699 | 1,110,136 | 0 | 0 | Mixed |
| BlackRock | 10,711,138 | 0 | 0 | 0 | For |
| Fidelity | 2,961,922 | 291,998 | 0 | 0 | Mixed |
| State Street | 2,826,749 | 145 | 0 | 0 | For |
| Delaware/Macquarie | 2,076,163 | 0 | 0 | 0 | For |
| Artisan | 2,028,425 | 0 | 0 | 0 | For |
| Charles Schwab | 1,720,061 | 0 | 0 | 0 | For |
| Thrivent | 1,695,443 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 1,623,745 | 0 | 0 | Against |
| TIAA | 1,460,481 | 0 | 0 | 0 | For |
| First Trust | 1,201,533 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,059,054 | 0 | 0 | 0 | For |
| Invesco | 1,004,224 | 0 | 0 | 0 | For |
| T. Rowe Price | 970,596 | 0 | 0 | 0 | For |
| Dimensional | 815,846 | 0 | 0 | 0 | For |
| Jackson National | 628,733 | 167,418 | 0 | 0 | Mixed |
| Equitable | 720,924 | 0 | 0 | 0 | For |
| American Century | 682,192 | 0 | 0 | 0 | For |
| Brighthouse | 557,341 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 500,392 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 482,634 | 0 | 0 | 0 | For |
| Federated Hermes | 468,804 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 461,935 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 380,360 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 0 | 372,820 | 0 | 0 | Against |
Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).
Combines 18 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.
HALOZYME THERAPEUTICS INC.’s own tally for this item (“2. The advisory vote on the compensation of the Company's named executive officers”): 102,860,435 for, 2,190,603 against — passed, per its Form 8-K filed April 26, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,892,835 | 0 | 0 | 0 | For |
| BlackRock | 10,711,138 | 0 | 0 | 0 | For |
| Artisan | 5,263,684 | 0 | 0 | 0 | For |
| Fidelity | 3,253,920 | 0 | 0 | 0 | For |
| State Street | 2,826,894 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 2,076,163 | 0 | 0 | 0 | For |
| Charles Schwab | 1,720,061 | 0 | 0 | 0 | For |
| Thrivent | 1,695,443 | 0 | 0 | 0 | For |
| JPMorgan | 1,623,745 | 0 | 0 | 0 | For |
| TIAA | 1,460,481 | 0 | 0 | 0 | For |
| First Trust | 1,201,533 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,059,054 | 0 | 0 | 0 | For |
| Invesco | 1,004,224 | 0 | 0 | 0 | For |
| T. Rowe Price | 970,596 | 0 | 0 | 0 | For |
| Dimensional | 815,846 | 0 | 0 | 0 | For |
| Jackson National | 796,151 | 0 | 0 | 0 | For |
| Equitable | 720,924 | 0 | 0 | 0 | For |
| American Century | 682,192 | 0 | 0 | 0 | For |
| Brighthouse | 557,341 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 500,392 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 482,634 | 0 | 0 | 0 | For |
| Federated Hermes | 468,804 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 461,935 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 380,360 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 372,820 | 0 | 0 | 0 | For |
Fund voting reports, all 123 managers: 63,368,956 for, 191,746 against, 61,921 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 6,135,781 | 0 | 0 | 0 | For |
| New York Life | 5,000,000 | 0 | 0 | 0 | For |
| BlackRock | 4,679,194 | 997 | 0 | 0 | For |
| SNYDER CAPITAL MANAGEMENT L P | 3,592,472 | 0 | 0 | 0 | For |
| AllianceBernstein | 3,399,831 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,941,522 | 0 | 0 | 0 | For |
| JPMorgan | 2,767,105 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 1,890,859 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 1,849,642 | 0 | 0 | 0 | For |
| Charles Schwab | 1,759,686 | 0 | 0 | 0 | For |
| Thrivent | 1,725,191 | 0 | 0 | 0 | For |
| Nuveen | 1,611,309 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 1,378,187 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,226,978 | 0 | 0 | 0 | For |
| Invesco | 1,184,319 | 0 | 0 | 0 | For |
| Stephens Investment Management Group LLC | 1,166,281 | 0 | 0 | 0 | For |
| Epoch Investment Partners, Inc. | 1,146,048 | 0 | 0 | 0 | For |
| Man Group plc | 1,087,890 | 0 | 0 | 0 | For |
| NEW YORK STATE COMMON RETIREMENT FUND | 917,782 | 0 | 0 | 0 | For |
| Granite Investment Partners, LLC | 734,205 | 0 | 0 | 0 | For |
| American Century | 703,278 | 0 | 0 | 0 | For |
| Lazard | 691,143 | 0 | 0 | 0 | For |
| Allspring | 638,223 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 557,295 | 0 | 0 | 0 | For |
| Northern Trust | 527,600 | 90 | 0 | 0 | For |
Institutional-manager reports, all 342 managers: 63,254,636 for, 1,426,977 against, 32,850 abstained, 908 not voted, 979 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
99.4% Approved · of votes cast
Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
HALOZYME THERAPEUTICS INC.’s own tally for this item (“4. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 114,912,469 for, 647,868 against — passed, per its Form 8-K filed April 26, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of HALOZYME THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 46,783 for).
The 123 asset managers below reported 60,309,472 for, 43,972 against, 61,921 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,892,835 | 0 | 0 | 0 | For |
| BlackRock | 10,711,138 | 0 | 0 | 0 | For |
| Fidelity | 3,253,920 | 0 | 0 | 0 | For |
| State Street | 2,826,749 | 145 | 0 | 0 | For |
| Delaware/Macquarie | 2,076,163 | 0 | 0 | 0 | For |
| Artisan | 2,028,425 | 0 | 0 | 0 | For |
| Charles Schwab | 1,720,061 | 0 | 0 | 0 | For |
| Thrivent | 1,695,443 | 0 | 0 | 0 | For |
| JPMorgan | 1,623,745 | 0 | 0 | 0 | For |
| TIAA | 1,460,481 | 0 | 0 | 0 | For |
| First Trust | 1,201,533 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,059,054 | 0 | 0 | 0 | For |
| Invesco | 1,004,224 | 0 | 0 | 0 | For |
| T. Rowe Price | 970,596 | 0 | 0 | 0 | For |
| Dimensional | 815,846 | 0 | 0 | 0 | For |
| Jackson National | 796,151 | 0 | 0 | 0 | For |
| Equitable | 720,924 | 0 | 0 | 0 | For |
| American Century | 682,192 | 0 | 0 | 0 | For |
| Brighthouse | 557,341 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 500,392 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 482,634 | 0 | 0 | 0 | For |
| Federated Hermes | 468,804 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 461,935 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 380,360 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 372,820 | 0 | 0 | 0 | For |
Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 1 item from the meeting of May 1, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 127,186,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.71% |
| 2 | BlackRock | 8.42% |
| 3 | Artisan | 4.14% |
| 4 | Fidelity | 2.56% |
| 5 | State Street | 2.22% |
| 6 | Delaware/Macquarie | 1.63% |
| 7 | Charles Schwab | 1.35% |
| 8 | Thrivent | 1.33% |
| 9 | JPMorgan | 1.28% |
| 10 | TIAA | 1.15% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | State Street | 4.82% |
| 2 | New York Life | 3.93% |
| 3 | BlackRock | 3.68% |
| 4 | SNYDER CAPITAL MANAGEMENT L P | 2.82% |
| 5 | AllianceBernstein | 2.67% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2.31% |
| 7 | JPMorgan | 2.18% |
| 8 | GW&K Investment Management, LLC | 1.49% |
| 9 | ArrowMark Colorado Holdings LLC | 1.45% |
| 10 | Charles Schwab | 1.38% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 12,860,199 | 10.11% | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 11,629,786 | 9.14% | Form 13F, quarter ended March 31, 2024 |
| Artisan Partners Limited Partnership | 6,689,058 | 5.26% | Proxy statement (DEF 14A), table as of February 26, 2024 |
| State Street | 6,487,303 | 5.10% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 3,027,384 | 2.38% | Form 13F, quarter ended March 31, 2024 |
| Helen I. Torley | 2,400,040 | 1.89% | Proxy statement (DEF 14A), table as of February 26, 2024 |
| Invesco | 2,088,410 | 1.64% | Form 13F, quarter ended March 31, 2024 |
| Northern Trust | 1,791,904 | 1.41% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 1,737,600 | 1.37% | Form 13F, quarter ended March 31, 2024 |
| Dimensional Fund Advisors | 1,688,229 | 1.33% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 127,186,000 shares outstanding, as reported by HALOZYME THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At HALOZYME THERAPEUTICS INC.'s shareholder meeting held April 25, 2024, in the 2023-2024 proxy season, 434 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 3,009 separate fund positions. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — HALOZYME THERAPEUTICS INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: HALOZYME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 26, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from HALOZYME THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
HALOZYME THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “HALOZYME THERAPEUTICS (HALO) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/halozyme-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.